Recent evidence suggests that MHC-II expression does not necessarily enable a tumor to directly present endogenous NeoAgs that can nonetheless access the class II presentation pathway or that MHCII+ tumor cells may not act as de facto APCs, potentially due to a lack of costimulatory molecules like CD80 (13, 14). Here, CD80 is linked to neoplasm.